top of page
Concept Visualization
MUNICH
PRECISION
ONCOLOGY
Where medical expertise meets
patient-centered care and cutting-edge technology.
MPO’s objective is to develop and establish dedicated theranostic centres globally. The centers will provide the highest standard and cutting edge technology in theranostic patient care.
The pilot center will be located in the greater Munich area and will serve as a functional technology demonstrator in cooperation with leading clinical, academic and industrial partners.
In the Munich Center, MPO will combine medical, scientific and technical expertise with world leading infrastructure to deliver patient-centred precision medicine. Furthermore, the Munich Center will serve as a location to develop, advance and deploy the latest in imaging, analysis and treatment technology, including a total body PET / CT scanner and advanced AI-based data analytics.
Scaling and Democratizing
Patient Access
Radiomolecular Precision Oncology, also referred to as Theranostics, merges therapy and diagnostics, enabling personalized cancer treatments based on individual biomarkers. Radioisotopes play a crucial role by providing targeted imaging and therapy. They can be used in both diagnostic scans and in delivering targeted radiation to tumors.
This dual approach enhances treatment precision and minimizes side effects, making it a powerful tool in modern medicine to effectively treat a growing variety of cancers.
What is Precision Oncology?
If we can see it,
we can treat it.
About
Munich Precision Oncology (MPO) is a German company founded by entrepreneurs, with long-standing expertise in setting-up and advancing successful companies in the field of radio molecular theranostics.
In collaboration with:
.png){kind=logo}
SIGN UP FOR THE LATEST UPDATES
bottom of page